Luis Guerra
Pulmonary Disease · Arlington, TXNPI 1295720787
Payments from drug & device makers
Across 126 payments — averaging $19.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$562
- AstraZeneca$350
- Mylan Specialty L.p.$303
- Regeneron Healthcare Solutions, Inc.$236
- Boehringer Ingelheim$221
- Insmed, Inc.$184
- plus $662 from 14 others
What the payments were for
- Food & beverage$2,519100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 30 | $562 |
| AstraZeneca | 17 | $350 |
| Mylan Specialty L.p. | 14 | $303 |
| Regeneron Healthcare Solutions, Inc. | 11 | $236 |
| Boehringer Ingelheim | 10 | $221 |
| Insmed, Inc. | 11 | $184 |
| Inspire Medical Systems, Inc. | 6 | $147 |
| Novartis | 6 | $124 |
| Grifols USA, LLC | 4 | $73 |
| Covis Pharma GmbH | 3 | $72 |
| Electromed, Inc. | 2 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Baxter Healthcare | 2 | $33 |
| Amgen | 2 | $27 |
| Boston Scientific | 1 | $24 |
| Genentech USA, Inc. | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Mallinckrodt Hospital Products Inc. | 1 | $14 |
| Harmony Biosciences LLC | 1 | $14 |
| Shionogi Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,519 in reported general payments places this provider in the 50th percentile of 904 pulmonary disease providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 99 | $86,811 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 60 | $40,398 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $11,775 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $6,532 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $2,160 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 48 | $1,249 |
| Montelukast Sodium | 24 | $177 |
| Prednisone | 28 | $134 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $562 | $98,586117 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $350 | $46,93077 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Arlington
- Charles AndrewsSan Antonio$17M
- Ivan RosasHouston$13.8M
- Shahrukh KureishyMcKinney$12.4M
- Raksha JainDallas$3.4M
- Kelly ChinDallas$2.7M
- Julie PhilleyTyler$2.4M
- Nicola HananiaHouston$2.2M
- Sandeep SahayHouston$2.1M
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.